True business success is driven by a powerful combination of innovation and purpose. New ideas, methods and processes are directed to creating new sources of value. And as executive compensation practitioners, we’re often asked how we design our reward programs to incentivize innovation.
Kenneth Kuk, Paul Platten and Chris Hamilton
Institutional Shareholder Services (ISS) is adding Economic Value Added (EVA) metrics in its proxy research reports this year, which is raising questions for companies.
Jim Kroll, Marc Roloson and Jamie Teo
Disclosure of human capital costs has long been required on companies’ financial statements, but they may soon have to be disclosed as an asset similar to equipment or intellectual property if a recommendation of the Securities and Exchange Commission’s (SEC’s) Investor Advisory Committee gains traction.
Don Delves, Andrew Goldstein, Ryan Resch and Steve Seelig
Canadian large cap companies in the S&P/TSX 60 index are expected to continue to show pockets of weakness for 2019 financial results, a continuation of generally tepid 2018 financial results.
Ming Young, Christina Le and Sebastién Morrissette
The growing worldwide attention given to the pay gap that exists between employees and CEOs and the need to tie pay to performance was reinforced with the publication of a strongly worded U.K. report on executive pay on March 26 prepared by a select committee of the U.K. Parliament’s House of Commons.
Jessica Norton and Anne-Sophie Blouin
Banks turned in a strong 2018 performance which was reflected in income statement and balance sheet metrics, but replicating these results could prove difficult in 2019, a possibility that is reflected in analysts’ expectations.
Daniel Potter and Michael Montane
2018 financial results in the energy sector were strong while shareholder returns declined. Analysts are less hopeful for 2019, and consequently, companies will have to carefully consider how to balance the interests of investors and the need to retain and incentivize key talent.
John Rhew and Ayush Gupta
Shareholder returns in the biopharma industry declined in 2018 even though financial results were fairly strong, mirroring a broader economic trend. Despite strong results in 2018, performance predictions in 2019 seem muted.
Mitchell Bardolf and Jang Han
You must be logged in to access this feature.